Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Paclitaxel

Docetaxel

Albumin-Bound Paclitaxel

Taxane

Tubulin Modulators

Antimitotic Agents

Glutamine

Intervention = Paclitaxel- CB-839 (Pac-CB) combination

1. Participants must self-identify as African ancestry (includes African American).
2. At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.

   * Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.
   * Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo.

Intervention = Pac-CB combination

1. Participants must self-identify as African ancestry (includes African American).
2. No prior systemic therapy for advanced or metastatic disease.

   * Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was \> 12 mo.

Intervention = Pac-CB combination

1. Participants do not self-identify as African ancestry.
2. Otherwise have the same criteria as Cohort 1.

Intervention = Pac-CB combination

1. Participants do not self-identify as African ancestry.
2. Otherwise have the same criteria as Cohort 2.

standard weekly paclitaxel in 28-day cycles

CB-839 administered as oral tablets twice daily (BID)

CB-839

Sam Whiting, MD, PhD

CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in participants of African ancestry and non-African ancestry with advanced triple negative breast cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839 will be administered in combination with the full approved dose of paclitaxel.

Participants will be enrolled into 4 cohorts, as follows:

* Cohort 1: patients of African ancestry with 2 or more lines of prior therapy for metastatic disease
* Cohort 2: patients of African ancestry with no prior lines of therapy for metastatic disease
* Cohort 3: same as cohort 1 but in patients of non-African ancestry
* Cohort 4: same as cohort 2 but in patients of non-African ancestry

Participants will be assigned to one of 4 arms depending on the number of prior lines of therapy they have received and whether or not they have African ancestry

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

ORR is defined as the percentage of patients with complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1criteria:

Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be assigned a status of CR or PR, changes in tumor measurements must be confirmed by repeat assessment performed no less than 4 weeks after the criteria for response were first met.

PFS was defined as time from the first dose date to the earlier of either progression of disease per RECIST v1.1 or death from any cause. The duration of progression-free survival was censored at the date of last radiographic disease if the patient was alive and progression free at the time of analysis data cutoff, disease progression or death occurred after missing data for 2 consecutive radiographic disease assessments, or patient received non-protocol TNBC treatment prior to documentation of disease progression. Kaplan-Meier product-limit estimates. Brookmeyer-Crowley methodology for a non-parametric 95% confidence interval (CI) is used.

Progressive Disease (PD) per RECIST 1.1: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.

Overall survival is defined as the time from the first dose date to death due to any cause. For patients alive at time of analysis, overall survival will be censored at the time when the patient is last known to be alive.Kaplan-Meier product-limit estimates. Brookmeyer-Crowley methodology for a non-parametric 95% CI is used. Median is defined to be the smallest observed survival time for which the value of the estimated survival function is less than or equal to 0.5.

Duration of response is defined as the time between the first documentation of a confirmed PR or a CR to the first documentation of PD or death, whichever occurs first. The duration of response will be censored at the date of last radiographic disease if the patient is alive and progression free at the time of database lock, disease progression or death occurs after missing data for two consecutive radiographic disease assessments, or patient receives non-protocol TNBC treatment prior to documentation of disease progression.

RECIST v1.1 criteria:

Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.

Clinical Benefit Rate is defined as the percentage of patients with best response of CR, PR, or SD per RECIST v1.1 criteria lasting ≥ 16 weeks for 3rd line + patients and ≥ 24 weeks for 1st line patients. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Calithera Biosciences, Inc

Per protocol, Grade 5 disease progression events are excluded from these tables. Disease progression includes events in the preferred terms of disease progression and malignant neoplasm progression.

Participants self-identifying as African ancestry (includes African American) with at least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane, received 800 mg CB-839 tablets PO BID on Days 1 through 28 of each 28-day cycle along with 80 mg/m\^2 of paclitaxel IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, unacceptable toxicity, initiation of another systemic anticancer treatment, death, or withdrawal of consent.

Cohort 1 - African Ancestry, 3rd Line+

Participants self-identifying as African ancestry (includes African American) with no prior systemic therapy for advanced or metastatic disease received 800 mg CB-839 tablets PO BID on Days 1 through 28 of each 28-day cycle along with 80 mg/m\^2 of paclitaxel IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, unacceptable toxicity, initiation of another systemic anticancer treatment, death, or withdrawal of consent.

Cohort 2 - African Ancestry, 1st Line

Participants not self-identifying as African ancestry (includes African American) with at least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane, received 800 mg CB-839 tablets PO BID on Days 1 through 28 of each 28-day cycle along with 80 mg/m\^2 of paclitaxel IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, unacceptable toxicity, initiation of another systemic anticancer treatment, death, or withdrawal of consent.

Cohort 3 - Non-African Ancestry, 3rd Line+

Participants not self-identifying as African ancestry (includes African American) with no prior systemic therapy for advanced or metastatic disease received 800 mg CB-839 tablets PO BID on Days 1 through 28 of each 28-day cycle along with 80 mg/m\^2 of paclitaxel IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, unacceptable toxicity, initiation of another systemic anticancer treatment, death, or withdrawal of consent.

Cohort 4 - Non-African Ancestry, 1st Line

Participants self-identifying as African ancestry (includes African American) with at least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane, received 800 mg CB-839 tablets orally (PO) twice daily (BID) on Days 1 through 28 of each 28-day cycle along with 80 mg/m\^2 of paclitaxel intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, unacceptable toxicity, initiation of another systemic anticancer treatment, death, or withdrawal of consent.

Total

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Black

White

Other, Not Specified

Race/Ethnicity, Customized

Study Director

Response Evaluable Analysis Set: all participants who had measurable disease at baseline, received at least 1 dose of study drug (telaglenastat or paclitaxel) and completed at least 1 post baseline tumor assessment.

Overall Response Rate (ORR)

PFS Evaluable Analysis Set: all participants who received at least 1 dose of any study-specific treatment (telaglenastat or paclitaxel).

Progression Free Survival (PFS) as Assessed by Investigator

Overall Survival (OS)

Response Evaluable Analysis Set: all participants who had measurable disease at baseline, received at least 1 dose of study drug (telaglenastat or paclitaxel) and completed at least 1 post baseline tumor assessment. Participants defined as responders.

Spots Global Cancer Trial Database for african ancestry